[1]赵亚男,解 琪,贾文旋,等.沙库巴曲缬沙坦联合托伐普坦治疗肺动脉高压所致右心衰竭疗效观察[J].陕西医学杂志,2024,(12):1680-1684.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.019]
　ZHAO Yanan,XIE Qi,JIA Wenxuan,et al.Efficacy of sacubitril/valsartan combined with tolvaptan in treatment of pulmonary arterial hypertension-induced right heart failure[J].,2024,(12):1680-1684.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.019]
点击复制

沙库巴曲缬沙坦联合托伐普坦治疗肺动脉高压所致右心衰竭疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1680-1684
栏目:
药物与临床
出版日期:
2024-12-05

文章信息/Info

Title:
Efficacy of sacubitril/valsartan combined with tolvaptan in treatment of pulmonary arterial hypertension-induced right heart failure
作者:
赵亚男1; 解 琪2; 贾文旋1; 李福龙3; 陈 璇1
(1.河北北方学院附属第一医院重症医学科,河北 张家口 075000; 2.河北北方学院附属第一医院耳鼻喉头颈外科,河北 张家口 075000; 3.河北北方学院附属第一医院麻醉科,河北 张家口 075000)
Author(s):
ZHAO Yanan; XIE Qi; JIA Wenxuan; LI Fulong; CHEN Xuan
(The First Hospital Affiliated to Hebei North University,Zhangjiakou 075000,China)
关键词:
肺动脉高压;  右心衰竭;  沙库巴曲缬沙坦;  托伐普坦;  右心功能;  运动耐力
Keywords:
Pulmonary arterial hypertension;  Right heart failure;  Sacubitril/valsartan;  Tolvaptan;  Right heart function;  Exercise endurance
分类号:
R 541.6
DOI:
DOI:10.3969/j.issn.1000-7377.2024.12.019
文献标志码:
A
摘要:
目的:观察沙库巴曲缬沙坦联合托伐普坦治疗肺动脉高压所致右心衰竭的疗效。方法:选取肺动脉高压致右心衰竭患者120例,通过单双号法分为常规组(60例,单号,给予沙库巴曲缬沙坦)与联用组(60例,双号,给予沙库巴曲缬沙坦联合托伐普坦)。比较两组患者右心功能[右心射血分数(RVEF)、右心舒张末期容积(RVEDV)和右心收缩末期容积(RVESV)]、运动耐力[步行6 min距离(6MWD)、峰值耗氧量(PeakVO2)]、血清相关物质[血清钠、血肌酐(Scr)、抗利尿激素(ADH)]、心衰标志物[N末端脑钠肽前体(NT-proBNP)、肌钙蛋白I(cTnI)、血管紧张素(PRA)]及药物不良反应。结果:治疗后,两组RVEF上升,RVEDV和RVESV下降,且联用组RVEF高于常规组,RVEDV和RVESV低于常规组(均P<0.05); 两组6MWD和PeakVO2上升,VE/VCO2 slop下降,且联用组6MWD和PeakVO2高于常规组,VE/VCO2 slop低于常规组(均P<0.05); 两组血清钠上升,Scr和ADH下降,且联用组血清钠高于常规组,Scr和ADH低于常规组(均P<0.05); 两组NT-proBNP、cTnI、PRA下降,且联用组低于常规组(均P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论:沙库巴曲缬沙坦联合托伐普坦可有效治疗肺动脉高压所致右心衰竭,提高患者右心功能与运动能力,调节血液生化指标,不良反应小,安全性高。
Abstract:
Objective:To observe the efficacy of sacubitril/valsartan combined with tolvaptan in the treatment of pulmonary arterial hypertension-induced right heart failure.Methods:A total of 120 patients with pulmonary arterial hypertension-induced right heart failure were divided into conventional group(60 cases,odd number,treated with sacubitril/valsartan)and combination group(60 cases,even number,treated with sacubitril/valsartan combined with tolvaptan)by odd and even number method.The right ventricular function(RVEF,RVEDV and RVESV),exercise endurance(6MWD and PeakVO2),serum related material(serum sodium,Scr,ADH),and heart failure markers(NT-proBNP,cTnI,PRA)and adverse drug reactions were compared between the two groups.Results:After treatment,RVEF increased,RVEDV and RVESV decreased in the two groups,and RVEF in the combination group was higher than that in the conventional group,and RVEDV and RVESV were lower than those in the conventional group(all P<0.05); 6MWD and PeakVO2 increased,VE/VCO2 slop decreased in the two groups,and 6MWD and PeakVO2 in the combination group were higher than those in the conventional group,VE/VCO2 slop was lower than that in the conventional group(all P<0.05); the serum sodium increased,Scr and ADH decreased in the two groups,and the serum sodium in the combination group was higher than that in the conventional group,and Scr and ADH were significantly lower than those in the conventional group(all P<0.05); the levels of NT-proBNP,cTnI and PRA decreased in the two groups,and those in the combination group were lower than those in the conventional group(all P<0.05).There were no statistical differences in the incidence rates of adverse drug reactions between two groups(P>0.05).Conclusion:Sacubitril/valsartan combined with tolvaptan can effectively treat right heart failure caused by pulmonary arterial hypertension,improve the patient's right heart function and exercise capacity,regulate blood biochemical indicators,with small adverse reactions and high safety.

参考文献/References:

[1] LUNA-LPEZ R,RUIZ-MARTÍN A,ESCRIBANO-SUBíAS P.Pulmonary arterial hypertension.Hipertensión arterial pulmonar[J].Med Clin(Barc),2022,158(12):622-629.
[2] THANDAVARAYAN R A,CHITTURI K R,GUHA A.Pathophysiology of acute and chronic right heart failure[J].Cardiol Clin,2020,38(2):149-160.
[3] MCGLOTHLIN D P,GRANTON J,KLEPETKO W,et al.ISHLT consensus statement:Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery[J].J Heart Lung Transplant,2022,41(9):1135-1194.
[4] 羡微微,刘桂清.沙库巴曲缬沙坦对射血分数降低性心衰患者血浆去甲肾上腺素和血清心肌肌钙蛋白I水平的影响研究[J].陕西医学杂志,2020,49(10):1306-1309.
[5] YANG J,MADANI M M,MAHMUD E,et al.Evaluation and management of chronic thromboembolic pulmonary hypertension[J].Chest,2023,164(2):490-502.
[6] KASPRZAK J D,GORCZYCA-GOWACKA I,SOBCZAK-KALETA M,et al.Pharmacotherapy of heart failure A.D.2023.Expert opinion of working group on cardiovascular pharmacotherapy,polish cardiac society[J].Kardiol Pol,2023,81(5):537-556.
[7] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等.中国肺动脉高压诊断与治疗指南(2021版)[J].中华医学杂志,2021,101(1):11-51.
[8] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.急性心力衰竭基层诊疗指南(2019年)[J].中华全科医师杂志,2019,18(10):925-930.
[9] MARRA A M,BENJAMIN N,CITTADINI A,et al.When pulmonary hypertension complicates heart failure[J].Cardiol Clin,2022,40(2):191-198.
[10] 俞婷,刘娜娜,钟青,等.沙库巴曲缬沙坦与传统血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂治疗阵发性房颤疗效对比观察[J].陕西医学杂志,2023,52(10):1407-1410.
[11] 孙红春,李敬,高茜,等.沙库巴曲缬沙坦和托伐普坦对慢性心力衰竭急性发作患者炎性指标的影响[J].中华老年心脑血管病杂志,2023,25(5):469-472.
[12] 李振军,郎立国,任红梅,等.托伐普坦片联合沙库巴曲缬沙坦钠片治疗心力衰竭伴低钠血症患者的临床研究[J].中国临床药理学杂志,2020,36(23):3900-3902,3906.
[13] MARON B A,BRITTAIN E L,HESS E,et al.Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension:A retrospective cohort study[J].Lancet Respir Med,2020,8(9):873-884.
[14] DOCHERTY K F,VADUGANATHAN M,SOLOMON S D,et al.Sacubitril/valsartan:Neprilysin inhibition 5 years after PARADIGM-HF[J].JACC Heart Fail,2020,8(10):800-810.
[15] VELIGRATLI F,ALEXANDROU D,SHAH S,et al.Tolvaptan and urea in paediatric hyponatraemia[J].Pediatr Nephrol,2024,39(1):177-183.
[16] 权乾坤,冯建军,李玺,等.重组人脑利钠肽、沙库巴曲缬沙坦、托伐普坦序贯治疗高龄射血分数降低的心力衰竭病人的疗效观察[J].实用老年医学,2021,35(9):957-961.
[17] 何婧瑜,赵芯晨,翟文亮,等.血清钠离子在老年女性急性心力衰竭患者30天主要不良心血管事件中的预测价值[J].中华老年心脑血管病杂志,2021,23(6):564-567.
[18] 郭传琦,艾健.温肾泄浊汤治疗慢性肾衰竭73例疗效研究[J].陕西中医,2023,44(9):1237-1240.
[19] 王毅,杨征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,48(4):470-472.
[20] MANDRAS S A,MEHTA H S,VAIDYA A.Pulmonary hypertension:A brief guide for clinicians[J].Mayo Clin Proc,2020,95(9):1978-1988.
[21] 徐先静,黄改荣,刘雪亚,等.托伐普坦治疗75岁及以上难治性心力衰竭患者的临床疗效观察[J].中华老年医学杂志,2020,39(9):1038-1041.
[22] BAYES-GENIS A,DOCHERTY K F,PETRIE M C,et al.Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP:A clinical consensus statement from the heart failure association of the ESC[J].Eur J Heart Fail,2023,25(11):1891-1898.
[23] AGDASHIAN D,DANIELS L B.What is the clinical utility of cardiac troponins in heart failure? Are they modifiable beyond their prognostic value?[J].Curr Heart Fail Rep,2023,20(1):33-43.
[24] 陈荣,谢海道,符秀曼,等.资生丸颗粒联合穴位贴敷治疗慢性肺心病肺气亏虚证疗效研究[J].陕西中医,2022,43(12):1793-1796.
[25] KINUGAWA K,MATSUKAWA M,NAKAMURA Y,et al.Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management:A retrospective cohort study using a medical claim database in Japan[J].J Cardiol,2023,82(1):35-42.

相似文献/References:

[1]王全宏,蔡宇星△,徐 辉.心脏超声在重症监护室肺动脉高压患者肺血管压力和右心功能评估中的应用分析*[J].陕西医学杂志,2019,(7):863.
　WANG Quanhong,CAI Yuxing,XU Hui..Application of echocardiography in evaluation of pulmonary vascular pressure and right heart function in patients with pulmonary hypertension in intensive care unit[J].,2019,(12):863.
[2]王 蕊,尚粉青△,叶玉兰,等.KLF2在肺动脉高压大鼠肺组织中的表达及机制探讨*[J].陕西医学杂志,2020,49(8):919.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.002]
　WANG Rui,SHANG Fenqing,YE Yulan,et al.Expression of KLF2 in pulmonary tissue of rats with pulmonary hypertension and its mechanism[J].,2020,49(12):919.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.002]

备注/Memo

备注/Memo:
基金项目:河北省医学科学研究课题(20241209); 河北省张家口市科技计划自筹经费项目(2322152D)
更新日期/Last Update: 2024-12-05